Trial reportOncogene2002
Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer.
Trial report in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 6 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- The association between CCND1 G870A polymorphism and colorectal cancer risk: A meta-analysis.Medicine · 2017Pooled it
- The CDH1 -160C/A polymorphism is associated with breast cancer: evidence from a meta-analysis.World journal of surgical oncology · 2016Pooled it
- E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer : a meta-analysis.International journal of colorectal disease · 2012Pooled it
- Pooled it
- Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies.PloS one · 2012Pooled it
- Cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations.International journal of colorectal disease · 2011Pooled it
- G870A Polymorphic Variants ofDiagnostics (Basel, Switzerland) · 2022Article
- The epithelial cadherin -160C/A polymorphism is associated with decreased risk of colorectal cancer: a case-control study.Clinical and experimental medicine · 2020Article
- Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.Medicina (Kaunas, Lithuania) · 2019Article
- MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.The pharmacogenomics journal · 2018Article
- DNMT1 regulates human endometrial carcinoma cell proliferation.OncoTargets and therapy · 2017Article
- Single Nucleotide Polymorphism (A870G) of theGastroenterology and hepatology from bed to bench · 2017Article
- CCND1 G870A polymorphism and colorectal cancer risk: An updated meta-analysis.Molecular and clinical oncology · 2016Article
- Revealing the role of VEGFA in clear cell sarcoma of the kidney by protein-protein interaction network and significant pathway analysis.Oncology letters · 2016Article
- Investigation ofOncoTargets and therapy · 2016Article
- Polymorphisms of cell cycle regulator genesOncology letters · 2015Article
- The significant association of CCND1 genotypes with colorectal cancer in Taiwan.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Cyclin D1 G870A polymorphism and glioma risk in a Chinese population.International journal of clinical and experimental medicine · 2015Article
- Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Regulatory Variants and Disease: The E-Cadherin -160C/A SNP as an Example.Molecular biology international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular basis for most non-HNPCC familial colorectal cancer cases is unknown, but there is increasing evidence that common genetic variants may play a role. We investigated the contribution of polymorphisms in two genes implicated in the pathogenesis of colorectal cancer, cyclin D1 (CCND1) and E-cadherin (CDH1), to familial and sporadic forms of the disease. The CCND1 870A/G polymorphism is thought to affect the expression of CCND1 through mRNA splicing and has been reported to modify the penetrance of HNPCC. Inactivation of E-cadherin is common in colorectal cancer, and truncating germline mutations have been reported to confer susceptibility to colorectal as well as diffuse gastric cancer. The -160A/C CDH1 polymorphism appears to affect expression of CDH1 and may therefore also confer an increased risk. We found a significantly higher frequency of CCND1 870A allele in 206 familial cases compared to 171 controls (P=0.03). Odds ratios in heterozygotes and homozygotes were 1.7 (95% CI: 1.0-2.66) and 1.8 (95% CI: 1.0-3.3) respectively. The difference was accounted for by an over-representation of A allele in non-HNPCC familial cases (P=0.007). Over-representation of the CCND1 A allele was also seen in sporadic colorectal cancer cases compared to controls but this did not attain statistical significance (P=0.08). No significant differences between the frequency of CDH1 -160A/C genotypes in familial, sporadic colorectal cancer cases and controls were seen, although a possible association between the low expressing A allele and right-sided tumours was detected in familial cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.